Please login to the form below

Not currently logged in
Email:
Password:

STX-100

This page shows the latest STX-100 news and features for those working in and with pharma, biotech and healthcare.

Biogen loses another pipeline drug to toxicity concerns

Biogen loses another pipeline drug to toxicity concerns

idiopathic pulmonary fibrosis (IPF) therapy STX-100. ... The demise of the drug draws a line under Biogen’s $75m upfront acquisition of Stromedix in 2012, when STX-100 was looking like a potentially important new therapy for fibrotic

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....